Document:

Exhibit 10.4

 

THIS INSTRUMENT AND ANY SECURITIES
ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR THE ISRAELI SECURITIES LAW 5728 – 1968, AS AMENDED, OR ANY STATE OR FOREIGN SECURITIES LAWS. THESE SECURITIES MAY NOT BE OFFERED,
SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

 

POLYRIZON LTD.

 

SAFE 

 

(Simple Agreement for Future
Equity)

 

THIS CERTIFIES THAT
in exchange for the payment by ______ (the “Investor”) of $[_______] (the “Purchase Amount”) on
[______], 2022, to Polyrizon Ltd., an Israeli private company (P.C.N. 513637025) (the “Company”), the Company
hereby issues to the Investor the right to certain shares of the Company, subject to the terms set forth below in this Simple Agreement
for Future Equity (this “SAFE”). Concurrently with the execution of this SAFE, the Company enters into similar Safes
(collectively, the “Additional SAFEs”); provided that the aggregate purchase amount of the Additional SAFEs
together with the Purchase Amount under this SAFE shall not exceed US$550,000 and based on the allocation listed on Annex A.

 

		1.	Events.

 

1.1 Automatic
Conversion in a Qualified Equity Financing. If there is a Qualified Equity Financing before the expiration or termination of this
SAFE, this SAFE will automatically convert into the number of Safe Shares equal to the Purchase Amount, divided by the Discount Price,
rounded up to the nearest whole number. In connection with the automatic conversion of this SAFE into SAFE Shares, each Investor will,
at the request of the Company in its sole discretion, execute and deliver to the Company all transaction documents related to the Qualified
Equity Financing; provided, that such documents (i) are the same documents to be entered into with the purchasers in the Qualified
Equity Financing, with appropriate variations for the SAFE Shares, as applicable, and (ii) have customary exceptions to any drag-along
applicable to the Investor, including (without limitation) limited representations, warranties, liability and indemnification obligations
for the Investor.

 

1.2 Optional
Conversion in a Non-Qualified Financing. If there is an Equity Financing by the Company which does not qualify as a Qualified Equity
Financing (“Non-Qualified Financing”), the outstanding Purchase Amount may be converted, at the written request of
the Investor made at Investor’s sole discretion within 30 days from the receipt of a written notice from the Company setting forth
the terms and conditions of such Non-Qualified Financing, into Safe Shares equal to the Purchase Amount divided by the Discount Price,
provided, that such documents are the same documents to be entered into with the investor of the Non-Qualified Financing, with
appropriate variations for the SAFE Shares if applicable as aforementioned. Each Investor will, at the request of the Company in its sole
discretion, execute and deliver to the Company all transaction documents related to the Non-Qualified Financing; provided, that
such documents are the same documents to be entered into with the purchasers in the Non-Qualified Financing, with appropriate variations
for the SAFE Shares, as applicable.

 

1.3 Liquidity
Event. If a Liquidity Event is consummated before the expiration or termination of this SAFE, this SAFE will automatically receive
immediately prior to, or concurrent with, the consummation of such Liquidity Event, from the Company, a number of Ordinary Shares, equal
to the Purchase Amount divided by the Liquidity Price. Each Investor will, at the request of the Company, in its sole discretion, execute
and deliver to the Company all documents related to the Liquidity Event, including lock-up undertakings, as may be applicable, provided
that such documents are the same documents to be entered into with the other shareholders of the Company with appropriate variations for
the SAFE Shares as applicable.

 

     

     

    

 

1.4 Public
Offering. If an Initial Public Offering is consummated before the expiration or termination of this SAFE, this SAFE will automatically
receive, immediately prior to and subject to, the unconditional closing of such Initial Public Offering, from the Company, a number of
Ordinary Shares, equal to the Purchase Amount divided by the price per share determined by the Initial Public Offering underwriter. Each
Investor will, at the request of the Company and\or the underwriter, execute and deliver to the Company all documents related to the Initial
Public Offering, as may be applicable, provided that such documents are the same documents to be entered into with the other shareholders
of the Company with appropriate variations for the SAFE Shares as applicable.

 

1.5 Mandatory
Conversion upon Drop Date. If the Purchase Amount has not been converted prior to July 31, 2023 (the “Drop Date”),
then on such Drop Date, this SAFE shall be automatically converted into such number of the most senior class of Equity Shares of the Company
then outstanding, equal to, the Purchase Amount, divided by the lowest price per share actually paid to the Company for such most senior
class of Equity Shares of the Company then outstanding, discounted by the Discount Rate, rounded up to the nearest whole number. The closing
of such mandatory conversion for the Investor shall occur within 14 days of the Drop Date.

 

1.6 Dissolution
Event. If there is a Dissolution Event before this instrument expires or terminates, following payment of all senior debt, the Company
will pay an amount equal to the Purchase Amount, immediately prior to, or concurrent with, the consummation of the Dissolution Event.
The Investor’s right to receive its Purchase Amount is (i) senior and in preference to any Distribution of any of the assets of
the Company to holders of outstanding Share Capital by reason of their ownership thereof and (ii) on par with payments for other SAFEs.
If the applicable Proceeds or assets of the Company legally available for distribution to the Investor herein or under the Additional
SAFEs (the “Dissolving Investors”), as determined in good faith by the Company’s board of directors, are insufficient
to permit the payment to the Dissolving Investors of their respective Purchase Amounts, then the entire assets of the Company legally
available for distribution will be distributed with equal priority and pro rata among the Dissolving Investors in proportion to
the Purchase Amounts they would otherwise be entitled to receive pursuant to this Section 1.6.

 

1.7 Termination.
This SAFE will automatically expire and terminate upon the earliest to occur of either: (i) the issuance of SAFE Shares to the Investors
pursuant to Section 1.1, Section 1.2, Section 1.3, Section 1.4, or Section 1.5, or (ii) the payment, or setting
aside for payment, of amounts due the Investors pursuant to Section 1.6.

 

		2.	Definitions

 

2.1 “Change
of Control” means (i) a transaction or series of related transactions as a result of which more than 50% of the shares
of the Company are transferred to any third party (ii) any reorganization, merger, consolidation, recapitalization or similar event
of the Company other than a single transaction or a series of related transactions as a result of which the shareholders of the Company
holding a majority of the voting securities immediately prior to such transaction or series of related transactions retain, immediately
after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding
voting securities of the Company or such other surviving entity (iii) a sale, lease grant of an exclusive license or other disposition
of all or substantially all of the assets of the Company, or (iv) a sale of all or substantially all of the shares of the Company.

 

2.2 “Discount
Price” means the lowest price per SAFE Share sold in the Equity Financing discounted by the Discount Rate.

 

2.3 “Discount
Rate” means 20% discount.

 

2.4
“Distribution” means the transfer to holders of Share Capital by reason of their ownership thereof of cash or
other property without consideration whether by way of dividend or otherwise, other than dividends on Ordinary Shares payable in
Ordinary Shares, or the purchase or redemption of Share Capital by the Company or its subsidiaries for cash or property other than:
(i) repurchases of Ordinary Shares held by employees, officers, directors or consultants of the Company or its subsidiaries pursuant
to an agreement providing, as applicable, a right of first refusal or a right to repurchase shares upon termination of such service
provider’s employment or services; or (ii) repurchases of Share Capital in connection with the settlement of disputes with any
shareholder.

 

    -2-

     

    

 

2.5
“Dissolution Event” means (i) a voluntary termination of operations, (ii) a general assignment for the benefit of
the Company’s creditors, or (iii) any other liquidation, dissolution or winding up of the Company (excluding a
Liquidity Event), whether voluntary or involuntary.

 

2.6 “Equity
Financing” means a Qualified Equity Financing or a Non-Qualified Financing.

 

2.7 “Initial
Public Offering” means the closing of the Company’s first firm commitment underwritten initial public offering of Ordinary
Shares pursuant to a registration statement filed under the Securities Act or of other similar securities law of another jurisdiction.
For the sake of this Agreement, the term Public Offering shall also mean a reverse merger or an investment in a Capital Pool Company (CPC).

 

2.8 “Liquidity Event” means a Change of Control.

 

2.9 “Liquidity Price” means the price per share of the Ordinary Shares sold or registered in a Liquidity Event multiplied
by the Discount Rate or the fair market value of the Ordinary Shares at the Liquidity Event multiplied by the Discount Rate.

 

2.10
“Ordinary Shares” means the ordinary shares of the Company.

 

2.11
“Proceeds” means cash and other assets (including, without limitation, consideration in shares) that are proceeds
from the Liquidity Event or the Dissolution Event, as applicable, and legally available for distribution.

 

2.12
“Qualified Equity Financing” means a bona fide transaction or series of transactions with the principal purpose
of raising capital, pursuant to which the Company issues and sells shares at a fixed pre-money valuation, in which the aggregate
proceeds to the Company are at least US $300,000 (excluding the SAFEs hereunder).

 

2.13
“SAFEs” means instruments containing future right to shares of the Company’s Share Capital, similar in form
and content to this SAFE, purchased by investor for the purpose of funding the Company’s business operations.

 

2.14 “SAFE
Shares” means the then most senior shares issued to the Investor in any Equity Financing, , having the identical rights, privileges,
preferences and restrictions as the Equity Shares, including, without limitation, liquidation preference, anti-dilution protection, registration
rights, preemptive rights, right of first refusal, voting and veto rights, or other rights, pro-rata to the respective amounts of investment,
and the Investor shall otherwise be deemed one of the investors in such Equity Financing for all purposes (including with respect to any
other securities, warrants or other or other rights granted to the investor, other than with respect to (if and to the extent applicable):
(i) the per share liquidation preference and the initial conversion price for purposes of price-based anti-dilution protection, which
will equal the Discount Price; (ii) the basis for any dividend rights, which will be based on the Discount Price; and (iii) any individual
rights granted to certain investors based on the size of their investment or number of shares they will receive (subject to the same minimum
holding requirements if applicable). The right to receive SAFE Shares shall also include the right to receive warrants or other convertible
instruments granted to the investors in the Equity Financing, if granted. For avoidance of doubt it is hereby clarified that if the Company
has no preferred class of shares in its share capital the SAFE Shares shall mean Ordinary Shares of the Company.

 

2.15 “Equity
Shares” means the shares of a series of Shares issued to the investor investing new money in the Company in connection with
the initial closing of the Equity Financing.

 

2.16 “Share
Capital” means the share capital of the Company, including, without limitation, Ordinary Shares and, if applicable, preferred
Shares of the Company.

 

2.17
“Subsequent Convertible Securities” means convertible securities that the Company may issue after the issuance of
this instrument with the principal purpose of raising capital, including but not limited to, other SAFEs, convertible debt
instruments and other convertible securities. Subsequent Convertible Securities excludes options issued pursuant to any equity
incentive or similar plan of the Company.

 

    -3-

     

    

 

		3.	Company Representations.

 

3.1 The
Company is a corporation duly organized and validly existing under the laws of the state of Israel, and has the power and authority to
own, lease and operate its properties and carry on its business as now conducted.

 

3.2 The
execution, delivery and performance by the Company of this SAFE is within the power of the Company and has been duly authorized by all
necessary actions on the part of the Company. This SAFE constitutes a legal, valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating
to or affecting the enforcement of creditors’ rights generally and general principles of equity. The Company is not in violation
of (i) its current articles of association, (ii) any material statute, rule or regulation applicable to the Company or (iii) any material
indenture or contract to which the Company is a party or by which it is bound, where, in each case, such violation or default, individually,
or together with all such violations or defaults, could reasonably be expected to have a material adverse effect on the Company.

 

3.3 The
performance and consummation of the transactions contemplated by this SAFE do not and will not: (i) violate any material judgment,
statute, rule or regulation applicable to the Company; (ii) result in the acceleration of any material indenture or contract to which
the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any lien on any property, asset
or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable to
the Company, its business or operations.

 

3.4 No
consents or approvals are required in connection with the performance of this SAFE, other than: (i) the Company’s corporate approvals;
(ii) necessary corporate approvals for the authorization of the Company’s Share Capital issuable pursuant to Section 1.

 

3.5 To
its knowledge and without conducting any specific investigation, the Company owns or possesses (or can obtain on commercially reasonable
terms) sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information,
processes and other intellectual property rights necessary for its business as now conducted, without any conflict with, or infringement
of the rights of, others.

 

		4.	Investor Representations.

 

4.1 The
Investor has full legal capacity, power and authority to execute and deliver this SAFE and to perform its obligations hereunder. This
SAFE constitutes valid and binding obligation of the Investor, enforceable in accordance with its terms, except as limited by bankruptcy,
insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general
principles of equity.

 

4.2 The
Investor had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the
offering of the Share Capital with the Company’s management and to consult with its advisors with respect to such matters.

 

4.3 The
Investor understands that no public market now exists for the Share Capital, and that the Company has made no assurances that a public
market will ever exist for the Share Capital.

 

		5.	Preferable Amendment of Terms.

 

If the Company amends the
terms of this SAFE to accommodate additional investors' terms or issues any Subsequent Convertible Securities with terms more favorable
of this SAFE prior to termination of this instrument, the Company will promptly provide the Investor with written notice thereof, together
with a copy of all documentation relating to such amendment or Subsequent Convertible Securities. In the event an Investor determines
that the amended terms of this SAFE or terms of the Subsequent Convertible Securities are preferable to the terms of this instrument,
such Investor will notify the Company in writing. Promptly after receipt of such written notice from the Investor, the Company agrees
to amend and restate this instrument to be identical to the instrument(s) evidencing the amendment or Subsequent Convertible Securities.

 

    -4-

     

    

 

		6.	Tax; Expenses.

 

Each party shall bear its
own expenses and taxes arising hereof. Any taxes, levies, charges and other duties or other amounts, that are levied or due in connection
with the transfer of the Investor’s portion of the Purchase Amount and/or the issuance of any shares to the Investor, shall be borne
by the Investor.

 

		7.	Miscellaneous.

 

7.1 Any
provision of this instrument may be amended, waived or modified only upon the written consent of the Company and the Investor.

 

7.2 Any
notice required or permitted by this SAFE will be deemed sufficient when delivered personally or by overnight courier or sent by email
to the relevant address listed on the signature page, or 7 days after being deposited in the mail as certified or registered mail with
postage prepaid, addressed to the party to be notified at such party’s address listed on the signature page, as subsequently modified
by written notice.

 

7.3 The
Investor is not entitled, as holder of this SAFE, to vote or receive dividends or be deemed a holder of Share Capital for any purpose,
nor will anything in this SAFE be construed to confer on the Investor, as such, any rights of a shareholder of the Company or rights to
vote for the election of directors or on any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to
any corporate action or to receive notice of meetings, or to receive subscription rights or otherwise until shares have been issued on
the terms described herein.

 

7.4 Neither
this SAFE nor the rights contained herein may be assigned, by operation of law or otherwise, by either party without the prior written
consent of the other; provided, however, that this instrument and/or the rights contained herein may be assigned without the Company’s
consent by the Investor, to any other entity who directly or indirectly, controls, is controlled by or is under common control with such
Investor, including, without limitation, any general partner, managing member, officer or director of such Investor, or any venture capital
fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management
company with, such Investor, and provided, however, that the Company may assign this SAFE in whole, without the consent of the
Investor, in connection with a reincorporation to change the Company’s domicile.

 

7.5 In
the event any one or more of the provisions of this SAFE is for any reason held to be invalid, illegal or unenforceable, in whole or in
part or in any respect, or in the event that any one or more of the provisions of this SAFE operate or would prospectively operate to
invalidate this SAFE, then and in any such event, such provision(s) only will be deemed null and void and will not affect any other provision
of this SAFE and the remaining provisions of this SAFE will remain operative and in full force and effect and will not be affected, prejudiced,
or disturbed thereby.

 

7.6 All
rights and obligations hereunder will be governed exclusively by the laws of the State of Israel, without regard to the conflicts of law
provisions of such jurisdiction and the competent courts of the city of Tel Aviv, Israel shall have exclusive jurisdiction with respect
to all matters arising out of or related to this instrument.

 

7.7 This
SAFE may be executed in any number of counterparts and at one or more times, each of which containing the signature of any of each of
the parties shall be deemed an original but all of which together shall constitute one and the same instrument.

 

[Next Page - Signature Page]

 

    -5-

     

    

 

[Signature Page - Polyrizon
Ltd. - 2021 SAFE]

 

IN WITNESS WHEREOF, the
undersigned have caused this instrument to be duly executed and delivered.

 

COMPANY:

 

POLYRIZON LTD.

 

	By:	 	 
	Name: 	 	 
	Title:	 	 

 

INVESTOR:

 

[Name of Investor]

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

    -6-

     

    

 

Annex A

 

	Name of Shareholder	 	Address	 	Purchase Amount (S$)	 	SignatureEX-10.1

  Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

  Exhibit 10.1

  SECOND Amendment

  to the EXCLUSIVE License AGREEMENT

  dated 8/26/2019

    

  This SECOND AMENDMENT to the Exclusive License Agreement dated August 26th, 2019, (“ORIGINAL LICENSE AGREEMENT”), is made the date of last signature (“SECOND AMENDMENT EFFECTIVE DATE”) by and between The Curators of the University of Missouri, a public corporation of the State of Missouri having an office at Technology Advancement Office, University of Missouri, 440a Bond Life Sciences Center, Columbia, MO 65211 (“UNIVERSITY”) and Decibel Therapeutics, Inc. a Delaware for-profit corporation having offices at 1325 Boylston Street, Suite 500, Boston, MA 02215 (“LICENSEE”).  UNIVERSITY and LICENSEE may sometimes be referred to herein as a “Party” or “Parties” as the case may be. 

    

  WHEREAS, LICENSEE and UNIVERSITY desire to amend the ORIGINAL LICENSE AGREEMENT, as was amended by a first amendment dated August 26, 2019 ("FIRST AMENDMENT").  The FIRST AMENDMENT deleted sections 3.01(e) and 5.02 of the ORIGINAL LICENSE AGREEMENT in their entirety and replaced them with substitute provisions.

    

  WHEREAS, through this SECOND AMENDMENT the PARTIES desire to revise certain terms related to Milestone Payments as provided for in the ORIGINAL LICENSE AGREEMENT and as was amended by the FIRST AMENDMENT.

    

  NOW, THEREFORE, in consideration of the foregoing premises and the covenants, representations and warranties contained herein, the Parties agree to amend the ORIGINAL LICENSE AGREEMENT and amended by the FIRST AMENDMENT as follows:  

    

  1.Definitions. For all purposes of this SECOND AMENDMENT, all capitalized terms used herein shall have the meanings attributed to them by the ORIGINAL LICENSE AGREEMENT and the FIRST AMENDMENT unless otherwise amended herein.

    

  2.Section 3.01 (e) of the ORIGINAL LICENSE AGREEMENT as was amended by the FIRST AMENDMENT is hereby stricken in its entirety and replaced with the following text:

  (e)  Milestone Payments. LICENSEE shall pay UNIVERSITY a milestone payment fee in accordance with the following schedule:

  (i)Regulatory Milestone Payments to be paid for each LICENSED PRODUCT:

  1)Upon [**] for each LICENSED PRODUCT in the OTOFERLIN LICENSED SUBFIELD, LICENSEE shall pay [**] dollars ($[**]), and [**] dollars ($[**]) for each LICENSED PRODUCT in the [**] LICENSED SUBFIELD.

  2)Upon [**], with each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]).

  3)Upon [**] with each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]).

   

  

   

  4)Upon [**] with each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]).

  5)Upon [**] of each LICENSED PRODUCT, LICENSEE shall pay [**] dollars ($[**]).

    

  In the event that a milestone is met and a prior milestone has not been met, then, the later and all prior unpaid milestone amounts will be combined and will be due upon the occurrence of the later milestone. For example, a [**] would result in LICENSEE owing [**] dollars ($[**]) due upon [**].

    

  For clarity, for each LICENSED PRODUCT in the OTOFERLIN LICENSED SUBFIELD achieving regulatory approval in the US, LICENSEE will owe UNIVERSITY a total amount in Regulatory Milestone Payments of seven hundred eighty thousand dollars ($780,000) for such LICENSED PRODUCT. Furthermore, for each LICENSED PRODUCT in the [**] LICENSED SUBFIELD achieving regulatory approval in the US, LICENSEE will owe UNIVERSITY a total amount in Regulatory Milestone Payments of seven hundred eighty thousand dollars ($772,500) for such LICENSED PRODUCT.

    

  (ii)Sales Milestone Payments to be paid for each LICENSED PRODUCT include:

  1)Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]), LICENSEE shall pay [**] dollars ($[**]).

  2)Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]), LICENSEE shall pay [**] dollars ($[**])

  3)Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]), LICENSEE shall pay [**] dollars ($[**])

  4)Upon cumulative NET SALES of each LICENSED PRODUCT in the US exceeding [**] dollars ($[**]),LICENSEE shall pay [**] dollars ($[**]).

    

  By way of example, should LICENSEE develop two LICENSED PRODUCTS (i.e., two different commercial products), then each of the foregoing milestones shall be payable for each of LICENSED PRODUCTS. Milestone fees are non-refundable. Royalty payments in a given license year shall not be creditable against any milestone fees.

    

  3.Section 5.02 of the ORIGINAL LICENSE AGREEMENT as was amended by the FIRST AMENDMENT is hereby stricken in its entirety and replaced with the following text:

  Section 5.02 UNIVERSITY shall have the right, at UNIVERSITY’s sole discretion, to either terminate or render this license nonexclusive in an individual LICENSED FIELD and/or individual country or countries within the LICENSED TERRITORY if LICENSEE or its SUBLICENSEE (if applicable):

    

  (a)In the OTOFERLIN LICENSED SUBFIELD:

  (i)Has not [**] for a LICENSED PRODUCT targeting the otoferlin gene by [**].

  (ii)Has not [**] for a LICENSED PRODUCT targeting the otoferlin gene [**] by [**].

  2

  

   

  (iii)Has not [**] for a LICENSED PRODUCT [**] targeting the otoferlin gene by the [**].

  (iv)Has not [**] targeting the otoferlin gene by [**].

    

  (b)In the [**] LICENSED SUBFIELD:

  (i)Has not [**] of the [**] gene [**] by [**].

  (ii)Has not [**] for a LICENSED PRODUCT targeting the [**] gene by [**].

  (iii)Has not [**] for a LICENSED PRODUCT targeting the [**] gene [**] by [**]. 

  (iv)Has not [**] for a LICENSED PRODUCT [**] targeting the [**] gene by [**].

  (v)Has not [**] for a LICENSED PRODUCT [**] targeting the [**] gene by [**].

  (c)Achieved [**] for any LICENSED PRODUCT [**] withi [**].

    

  4.A new Section 11.17 is added with following text:

  Section 11.17 If this Agreement has a total potential value of $100,000 or more, and if Sponsor is a company with ten (10) or more employees, then Sponsor certifies that it, and any company affiliated with it, does not boycott Israel and will not boycott Israel during the term of this Agreement. In this paragraph, the terms “company” and “boycott Israel” shall have the meanings described in Section 34.600 of the Missouri Revised Statutes.

  5.All other terms and conditions of the ORIGINAL LICENSE AGREEMENT and FIRST AMENDMENT are hereby ratified and reaffirmed and continue in full force and effect. This SECOND AMENDMENT does not act to change any other provisions or alter the timing of any other payments or diligence items due in the ORIGINAL LICENSE or FIRST AMENDMENT except as expressly provided herein.  

  [Signature page follows.]

  3

  

   

    

  IN WITNESS WHEREOF, the Parties hereto have executed this SECOND AMENDMENT by their duly authorized officers or representatives. 

   

  					
	THE CURATORS OF THE
	 
	LICENSEE

	UNIVERSITY OF MISSOURI 
	 
	 
	 

	 
	 
	 
	 
	 

	BY:
	/s/ Lisa Lorenzen
	 
	 BY:
	/s/ Laurence Reid

	 
	 
	 
	 
	 

	NAME:
	Lisa Lorenzen
	 
	NAME:
	 Laurence Reid

	TITLE:
	Assistant Vice Chancellor 
	 
	TITLE: 
	 Chief Executive Officer

	 
	Technology Advancement
	 
	 
	Decibel Therapeutics

	 
	 
	 
	 
	 

	DATE
	5/3/2022
	 
	DATE
	5/3/2022

   

  4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]